Ftse Mib
34.186,18
0,07%
DAX
19.909,14
-0,25%
S&P 500
5.881,63
-0,43%
NASDAQ
19.310,79
-0,90%
Bitcoin
94.946,78
0,59%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Incannex Healthcare Ltd (IXHL) Incannex Healthcare Ltd (IXHL) Notizie

IXHL

Incannex Healthcare (IXHL)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IXHL
DataOraFonteTitoloSimboloCompagnia
11/12/202422:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IXHLIncannex Healthcare Ltd
09/12/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IXHLIncannex Healthcare Ltd
06/12/202422:23Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:IXHLIncannex Healthcare Ltd
26/11/202422:06Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:IXHLIncannex Healthcare Ltd
14/11/202422:05GlobeNewswire Inc.Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business UpdatesNASDAQ:IXHLIncannex Healthcare Ltd
12/11/202412:07Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:IXHLIncannex Healthcare Ltd
12/11/202412:04Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:IXHLIncannex Healthcare Ltd
06/11/202422:19Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:IXHLIncannex Healthcare Ltd
31/10/202421:10Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:IXHLIncannex Healthcare Ltd
24/10/202422:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IXHLIncannex Healthcare Ltd
24/10/202422:48Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IXHLIncannex Healthcare Ltd
24/10/202413:30GlobeNewswire Inc.Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical OfficerNASDAQ:IXHLIncannex Healthcare Ltd
30/09/202422:01GlobeNewswire Inc.Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business UpdatesNASDAQ:IXHLIncannex Healthcare Ltd
30/09/202413:30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:IXHLIncannex Healthcare Ltd
10/09/202414:00GlobeNewswire Inc.Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena InvestorsNASDAQ:IXHLIncannex Healthcare Ltd
10/09/202413:00Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:IXHLIncannex Healthcare Ltd
05/08/202413:30GlobeNewswire Inc.FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to ProceedNASDAQ:IXHLIncannex Healthcare Ltd
30/07/202413:30GlobeNewswire Inc.Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42XNASDAQ:IXHLIncannex Healthcare Ltd
30/05/202413:30GlobeNewswire Inc.Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep ApneaNASDAQ:IXHLIncannex Healthcare Ltd
07/05/202413:30GlobeNewswire Inc.Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorderNASDAQ:IXHLIncannex Healthcare Ltd
16/04/202414:00GlobeNewswire Inc.Incannex Healthcare Inc. Quarterly Update, Q1 2024NASDAQ:IXHLIncannex Healthcare Ltd
28/02/202413:30GlobeNewswire Inc.Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety DisorderNASDAQ:IXHLIncannex Healthcare Ltd
16/02/202413:30GlobeNewswire Inc.Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking CessationNASDAQ:IXHLIncannex Healthcare Ltd
14/02/202412:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IXHLIncannex Healthcare Ltd
01/02/202413:30GlobeNewswire Inc.Clarion Clinics Open for Psychedelic-Assisted TreatmentsNASDAQ:IXHLIncannex Healthcare Ltd
24/01/202422:05GlobeNewswire Inc.Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid ArthritisNASDAQ:IXHLIncannex Healthcare Ltd
18/01/202414:22GlobeNewswire Inc.Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis CommencesNASDAQ:IXHLIncannex Healthcare Ltd
17/01/202413:30GlobeNewswire Inc.Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep ApneaNASDAQ:IXHLIncannex Healthcare Ltd
21/12/202322:05GlobeNewswire Inc.Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in AustraliaNASDAQ:IXHLIncannex Healthcare Ltd
20/12/202323:05Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IXHLIncannex Healthcare Ltd
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IXHL

La tua Cronologia

BITMOT
886616
Oat Green Bond Tf 0,5% G...
BTRX
ADAUSD
Cardano
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network